Home›Companies›Biotech & Pharma›Ambagon Therapeutics

Ambagon Therapeutics Inc.

Develops experimental cancer drugs that stabilize interactions between proteins.

Updated Nov 18, 2026·Latest SEC filing Feb 7, 2025·Suggest an edit

About Ambagon Therapeutics

Ambagon Therapeutics is a private company based in Eindhoven, Netherlands, incorporated in 2020 in Delaware. It has reported $55,399,994 raised in three offerings on Form D since August 2020. Its chief executive is Christian Ottmann.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 24, 2025Feb 7, 2025$5,000,000of $12.0M target4$1.2MEquityRule 506(b)Form D ↗
Jan 5, 2022Jan 19, 2022amended Jun 1, 2022$44,999,996of $84.9M target9$4.9MEquityRule 506(b)Form D/A ↗1 earlier filing
Dec 7, 2021Aug 3, 2020amended Dec 22, 2021$5,399,998fully sold8$674KEquityRule 506(b)Form D/A ↗2 earlier filings
Total, three offerings$55,399,994

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Ambagon Therapeutics's Form D filed Feb 7, 2025.

MM
Melissa McCracken
Partner, Nextech Invest and director
First appears on the Form D that Ambagon Therapeutics filed on January 19, 2022; on 3 of its 6 filings.
JS
Josh Seidenfeld
Executive officer
First appears on the amended Form D that Ambagon Therapeutics filed on August 20, 2021; on 5 of its 6 filings.
Christian Ottmann
Christian Ottmann
Co-Founder & Chief Executive Officer
On every Form D that Ambagon Therapeutics has filed: 6 filings, from Aug 3, 2020 to Feb 7, 2025.

Earlier filings also listed

  • Scott Clarke · chief executive officer and director
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 4 of its 6 filings.
  • Roel Bulthuis · director
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 5 of its 6 filings.
  • Peter Dudek · director
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 5 of its 6 filings.
  • Nancy Pryer · executive officer
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 4 of its 6 filings.
  • Michelle Arkin · director
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 5 of its 6 filings.
  • Margarita Chavez · director
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 5 of its 6 filings.
  • Janwillem Naesens · director
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 5 of its 6 filings.
  • Bryan Miller · executive officer
    Last listed on the amended Form D that Ambagon Therapeutics filed on June 1, 2022; on 4 of its 6 filings.

Sources

  1. SECAmbagon Therapeutics Inc. Form D, filed Jan 19, 2022
  2. SECAmbagon Therapeutics Inc. Form D/A, filed Aug 20, 2021
  3. SECAmbagon Therapeutics Inc. Form D, filed Aug 3, 2020
  4. SECAmbagon Therapeutics Inc. filing history
  5. CompanyContact
  6. CompanyAbout